Pharmacodynamic separation (PDS) of gemcitabine (Gem) and the epidermal growth factor receptor (EGFR) inhibitor erlotinib (E) in patients (Pts) with advanced pancreatic cancer: Phase II results.
Thomas John Semrad
Consultant or Advisory Role - Amgen; Genomic Health
Research Funding - Millennium; Novartis
Other Remuneration - Novartis (Speakers Bureau)
Heinz-Josef Lenz
Honoraria - Genentech/Roche
Research Funding - Genentech/Roche
I-Yeh Gong
No relevant relationships to disclose
Michael S. Tanaka
No relevant relationships to disclose
Courtney Eddings
No relevant relationships to disclose
Nichole Mahaffey
No relevant relationships to disclose
Philip C. Mack
No relevant relationships to disclose
Laurel Beckett
No relevant relationships to disclose
Primo Lara
Consultant or Advisory Role - Agennix; Genentech; Immunogen; Medivation; Pfizer; Teva
Honoraria - Elsevier
Research Funding - Genentech/Roche; GlaxoSmithKline; Janssen Oncology; Millennium; NCI